Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab.

The incidence of ILD in patients with HNSCC treated with cetuximab was <5%, but most of the ILD cases were severe. High KL-6 and smoking histories might be predictive for ILD among patients with HNSCC.